Poll

Poll: RAPID3 for Clinical Use

02/20/2019

Do you use routine assessment of patient index data 3 (RAPID3) when assessing patients with rheumatoid arthritis?

Yes

No, I use a different standard for measuring disease activity

Stay in the Know

Rheumatology & Arthritis Newsletter

Partner Spotlight

Axial Involvement in SpA: A Patient-Centered Exploration, Chapter 1

Popular Articles

Sponsored

Test Your Knowledge

Obesity as a Chronic Inflammatory State Impacting Spondyloarthritis (SpA)

10/01/2024

Understand obesity as a chronic disease and a contributor to underlying inflammatory activity that directly and negatively impacts patients with spondyloarthritis (SpA).

Understand obesity as a chronic...

10/01/2024

Rheumatology & Arthritis

Sponsored

Test Your Knowledge

Impact of Comorbid Obesity on Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA) Patient Outcomes

10/01/2024

Assess your understanding of the impact of obesity on psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patient outcomes.

Assess your understanding of the...

10/01/2024

Rheumatology & Arthritis

Sponsored

Test Your Knowledge

Importance of Holistic Management of Obesity in Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA) Patient Populations

10/01/2024

Take this quick quiz to deepen your understanding of the role holistic management plays in improving outcomes for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients with obesity.

Take this quick quiz to deepen...

10/01/2024

Rheumatology & Arthritis

Sponsored

Charting the Course Toward Improved Patient Outcomes in Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA)

11/10/2023

In this white paper, leading experts in the treatment of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) summarize the educational gaps among health care providers that are preventing optimal patient care....

In this white paper, leading...

11/10/2023

Dermatology

FDA Alert

FDA Approves Bimekizumab for PsA, nr-axSpA and AS

09/23/2024

Rebecca Mashaw ;

Already approved for plaque psoriasis, bimekizumab is designed to selectively inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F).

Already approved for plaque...

09/23/2024

Rheumatology & Arthritis

Poll: RAPID3 for Clinical Use

Yes

No, I use a different standard for measuring disease activity

Stay in the Know

Partner Spotlight

Popular Articles

Specialties

Events

Year Round Education

HMP Global Products